Narcotic Drugs (Licence Charges) Regulation 2016

The regulation centres on several defined terms that give it operational effect. A licence year is the period for which charge is imposed. For licences other than those preserved or converted by the 2021 amendments, the licence year is 12 months starting on the day the licence comes into force or a later anniversary of that day. For preserved licences, the licence year is 12 months starting on the day the licence came into force or a later anniversary. For converted licences (where multiple original licences were merged into a single licence), the first licence year is 12 months ending immediately before the earliest anniversary day of any original licence occurring after the commencement of the 2021 amending regulation, and subsequent years start from a later anniversary of that day. This asymmetry can produce a truncated first year for converted licences.

Commercial medicinal cannabis licence and non-commercial medicinal cannabis licence are defined by cross-reference to the Narcotic Drugs Regulation 2016 and the Narcotic Drugs Act 1967. The regulation does not define the substantive difference; it simply adopts those classes. The charge distinction is stark: commercial licence holders pay $28,310 every licence year; non-commercial holders pay the same only in year one.

Inspection type 1 is an inspection to monitor compliance with the Narcotic Drugs Act 1967 or instruments under that Act. Inspection type 2 is an inspection to verify information provided by the licence holder or another person about activities under the licence, its conditions, permits, or other matters. The charge for type 1 ($12,950) is nearly three times that for type 2 ($4,920), reflecting the relative intrusiveness or cost of the inspection. The regulation explicitly states that more than one charge is payable per year if more than one inspection occurs, meaning the total inspection charge bill is uncapped.

Other key concepts include permit (defined in the Narcotic Drugs Act), authorised inspector (also from the Narcotic Drugs Act), and law enforcement agency. The Regulatory Powers Act is referenced only to note that certain provisions of that Act apply because of Chapter 4 of the Narcotic Drugs Act 1967; this matters for enforcement but the regulation itself does not invoke those powers.

The amount of charge for cannabis-related manufacture licences was historically dealt with in earlier versions of section 6 but has been removed from the current text; those provisions are now subsumed under the medicinal cannabis licence framework. The transitional provisions in Part 3 preserve the application of old amounts for licence years that straddled amendment dates, often requiring pro-rata calculations.

The primary affected parties are the holders of medicinal cannabis licences issued under the Narcotic Drugs Act 1967. As at the most recent amendments, there are two classes: commercial and non-commercial. Commercial licence holders face a recurring fixed cost of $28,310 per licence year, plus inspection charges that can arise unpredictably. Non-commercial licence holders face the same initial cost but then zero annual charge thereafter, though they remain liable for inspection charges. This asymmetry creates a clear financial incentive to structure operations as non-commercial where possible, which may or may not align with the policy objectives of the enabling Act.

Applicants for new licences are indirectly affected because the charge for the first licence year is payable once the licence is granted. The regulation does not set an application fee; it sets the ongoing charge. Prospective licensees need to factor the $28,310 into their business plan for the first year regardless of licence class.

Authorised inspectors are affected in that the regulation underpins the cost-recovery mechanism for their inspections. The charges are payable by the licence holder, not by the inspector or the regulator. The regulator (the Office of Drug Control within the Department of Health) is affected because the regulation provides the legal basis for billing and collecting charges. The amounts are fixed, so any increase in the regulator's inspection costs that exceeds the prescribed amounts must be absorbed by the budget or requires an amendment to the regulation.

Agencies of the Commonwealth, states, and territories that conduct inspections (typically law enforcement agencies) are affected because inspection type 2 is specifically designed to verify information provided to them. The charge compensates for their inspection time. However, the regulation does not allocate the revenue to those agencies; it flows to consolidated revenue or the relevant appropriations.

The regulation does not directly affect patients, prescribers, or other participants in the medicinal cannabis market. However, the charges are a cost of business for licence holders, and those costs are likely passed downstream to patients or absorbed, depending on market conditions. The annual fixed charge is a barrier to entry, favouring larger operators who can spread the cost across higher volumes.

The regulation creates no duties or rights of its own; it is a subordinate instrument that quantifies charges. The primary duty flowing from the regulation is the obligation to pay the charge in the amount and for the period prescribed. The enabling Act (the Narcotic Drugs (Licence Charges) Act 2016) imposes the charge, and this regulation makes it calculable. Failure to pay the charge is not a direct offence under this regulation but would be a breach of the licence conditions under the Narcotic Drugs Act 1967, potentially leading to suspension or revocation.

A right that arises from the regulation is the right of a non-commercial licence holder to pay nil charge after the first year. That is a significant benefit conferred by subclassifying licences. Similarly, the regulation implicitly guarantees that a licence holder will not be charged more than prescribed amounts; the regulator cannot demand a higher fee.

The regulation also creates, by its existence, a right to certainty about the timing of charges. The licence year is defined, so a licence holder knows when the charge will fall due (on the start of each 12-month period). For preserved and converted licences, however, the transitional provisions can create ambiguity about the first licence year's end date, which may require careful calculation.

There is a duty to pay inspection charges when an inspection is carried out. The regulation does not give the licence holder a right to refuse an inspection; that is governed by the Narcotic Drugs Act 1967 and licence conditions. The inspection charge is a secondary obligation triggered by the regulator's decision to inspect. Note that inspection type 2 can be initiated based on information from third parties, including law enforcement; the licence holder may be charged for an inspection even if they are not the subject of a complaint, if the regulator decides to verify information.

The regulation does not provide any mechanism for disputing the amount of charge or for waiving it. Any such rights would be found in the enabling Act or in general administrative law.

This regulation does not itself create penalties for non-payment; it is purely a pricing instrument. However, the consequences of non-payment flow from the overarching regime. The Narcotic Drugs (Licence Charges) Act 2016, read with the Narcotic Drugs Act 1967, provides that charge is a debt due to the Commonwealth and may be recovered in a court of competent jurisdiction. More practically, a licence condition will require payment of charge as a condition of the licence remaining in force. Non-payment can therefore lead to suspension or cancellation of the licence under the Narcotic Drugs Act.

The regulation cross-references the Regulatory Powers (Standard Provisions) Act 2014 via section 4, noting that references to provisions of that Act are as they apply because of Chapter 4 of the Narcotic Drugs Act 1967. That chapter deals with monitoring and investigation powers, including civil penalty provisions. While the charge itself is not a penalty, failure to pay may be enforced through civil penalty proceedings under the Regulatory Powers Act if the enabling Act makes non-payment a contravention of a civil penalty provision. The regulation does not specify this; it is left to the substantive Act.

The inspection charges are also recoverable as debts. The regulation provides that more than one charge can be payable per year, meaning a licence holder could be liable for multiple inspection charges on top of the annual licence charge. There is no cap on total inspection charges per year. The regulator has discretion to conduct inspections, and the cost to the licence holder can be significant. The absence of a cap creates a potential for disproportionate enforcement costs.

The regulation itself contains no infringement notice provisions or criminal offences. Its enforcement relies entirely on the parent Act and the general law of debt recovery.

The regulation sits within a legislative hierarchy. Its parent is the Narcotic Drugs (Licence Charges) Act 2016, which is itself a companion to the Narcotic Drugs Act 1967. The Narcotic Drugs Act 1967 establishes the licensing scheme for cannabis activities, and this regulation provides the financial component. The Narcotic Drugs Regulation 2016 (the principal regulation) contains the substantive requirements for licence applications, conditions, and obligations, including section 54B which deals with payment of charge. This regulation sets the amounts; the principal regulation sets the due dates and method of payment.

The cross-reference to the Regulatory Powers (Standard Provisions) Act 2014 indicates that enforcement mechanisms such as monitoring powers, investigation powers, and civil penalty provisions are imported. This regulation does not activate those powers; it merely notes that the reference is to those provisions as they apply because of Chapter 4 of the Narcotic Drugs Act 1967.

State and territory laws also regulate medicinal cannabis, typically through poisons legislation or drugs and poisons acts. This regulation is a Commonwealth instrument and does not override state laws; it sits alongside them. A licence holder must comply with both Commonwealth licence charges and any state licensing or registration fees for cannabis activities. The regulation does not interact directly with those laws.

The application and transitional provisions in Part 3 show how this regulation interacts with earlier versions and with the Narcotic Drugs Amendment (Medicinal Cannabis) Act 2021. That Act restructured the licence framework, and this regulation had to be amended to align licence years and charge amounts. The transitional provisions ensure that charges are applied in a pro-rata manner where necessary, preventing double charging or gaps.

The regulation also interacts with the Legislation Act 2003, as noted in section 8's note about section 7 of the Acts Interpretation Act 1901 being preserved. This ensures that rights and liabilities accrued before an amendment are not extinguished.

The regulation has been amended multiple times, each time adjusting charge amounts, adding new licence classes, or clarifying transitional arrangements. The text itself records the following amending instruments, each with its own application provisions in Part 3:

• Narcotic Drugs (Licence Charges) Amendment (Cannabis) Regulations 2018: amended section 6, applying to licences granted on or after its commencement. This was likely the first operational adjustment after the scheme began.

• Narcotic Drugs (Licence Charges) Amendment (2020 Measures No. 1) Regulations 2020 (commenced 15 July 2020): updated the definition of licence year in section 5 and adjusted charge amounts. It included transitional provisions that distinguished between licence years starting before and after 15 July 2020.

• Narcotic Drugs (Licence Charges) Amendment (Cannabis-Related Manufacture Licences) Regulations 2020 (commenced 1 November 2020): added a class of cannabis-related manufacture licences and set charge amounts, including pro-rata formulae for licence years that straddled the commencement date. The current version of section 6 no longer distinguishes manufacture licences separately, suggesting they were later subsumed into the medicinal cannabis licence framework.

• Narcotic Drugs (Licence Charges) Amendment (Charge Amounts and Other Measures) Regulations 2021: further adjusted charge amounts for licence years starting on or after 1 July 2021, and for licence years ending on or after that date.

• Narcotic Drugs (Licence Charges) Amendment (Charge Amounts) Regulations 2023 (commenced 1 August 2023): amended section 6 and inserted section 6A (inspection charges). The inspection charges applied to inspections commenced on or after that date.

• Narcotic Drugs (Licence Charges) Amendment Regulations 2024 (commenced 1 July 2024): amended section 6 and section 6A for licence years and inspections starting on or after that date.

• Narcotic Drugs (Licence Charges) Amendment (Charge Amounts) Regulations 2025 (commenced 1 July 2025): the most recent amendment, applying to licence years and inspections starting on or after 1 July 2025.

The regulation has clearly been under active review, with annual or near-annual adjustments. The charge amounts have not been indexed to inflation; each amendment has set a new fixed figure. The 2023 amendment was notable for introducing the separate inspection charge regime, which was not present in the original 2016 regulation. The 2021 amendments appear to have been significant, aligning the regulation with the structural changes made by the Narcotic Drugs Amendment (Medicinal Cannabis) Act 2021, which created the commercial/non-commercial distinction and addressed preserved and converted licences.

The regulation text does not cite any cases, and there is no public record of litigation specifically challenging the charge amounts or the validity of this regulation. This is unsurprising for a subordinate instrument that sets fixed fees. Challenges would more likely be directed at the underlying licensing decisions or at the parent Act. The regulation's provisions are mechanical and do not involve discretionary decisions that would typically attract judicial review.

The transitional formulae for pro-rata charges in the 2020 amendments are complex and could theoretically be challenged if a licence holder argued that the calculation method produced an unfair result. However, no such challenge is recorded in the source. The use of the Regulatory Powers Act framework might give rise to disputes about the validity of inspection charges if an inspection was carried out without proper authorisation, but that would be a matter under the Narcotic Drugs Act, not this regulation.

Overall, the regulation appears to be one of the less-litigated parts of the medicinal cannabis regime. Its litigation history is effectively nil.

Several provisions can trap the unwary. The most significant is the uncapped nature of inspection charges. A licence holder could face multiple type 1 inspections in a year at $12,950 each, plus type 2 inspections at $4,920 each, with no limit. The regulator's discretion is unrestrained by this regulation. A single investigation could generate tens of thousands of dollars in charges, regardless of whether the licence holder is ultimately found compliant.

The licence year definition for converted licences is another trap. For licences that were the result of merging multiple original licences (under item 3 of Schedule 2 to the Narcotic Drugs Amendment (Medicinal Cannabis) Act 2021), the first licence year under this regulation may be shorter than 12 months. It ends immediately before the earliest anniversary day of any original licence occurring after the commencement of the 2021 amending regulation. A holder could face a charge for a partial year, then a full year charge on the subsequent anniversary. The calculation of that earliest anniversary day requires reconstructing what the licence years would have been for the original licences, which may be administratively burdensome.

Non-commercial licence holders are not exempt from inspection charges. They pay $28,310 in year one and nil annually thereafter, but they still owe inspection charges. An inspection-dense year could cost them more than the annual charge for a commercial holder. This may be overlooked by entities that obtain a non-commercial licence expecting no ongoing costs.

The regulation does not specify a deadline for payment; that is left to the Narcotic Drugs Regulation 2016 (section 54B). A holder must consult that instrument separately. Similarly, there is no provision for refunds if a licence is surrendered mid-year. The charge is fixed per licence year, so a holder who surrenders the licence after six months still owes the full annual charge.

The cross-references to the Regulatory Powers Act are easy to ignore but may have enforcement implications. The note in section 4 says that references to provisions of the Regulatory Powers Act are to those provisions as they apply because of Chapter 4 of the Narcotic Drugs Act 1967. That chapter includes powers of entry, search, and monitoring. An inspection charge may be triggered by an inspection conducted under those powers. The holder cannot refuse the inspection on grounds of cost.

Compliance requires a licence holder to understand the charge obligations and to budget for them. First, determine the correct class of licence (commercial or non-commercial). For a commercial licence, the annual charge is $28,310 per licence year. For a non-commercial licence, the charge is $28,310 for the first licence year and nil thereafter. The licence year starts on the day the licence comes into force, and then on each anniversary of that day. For preserved or converted licences, the first licence year may begin on a different date; the licence holder should obtain from the regulator a written confirmation of the licence year start date to avoid miscalculation.

Payment of the annual charge must be made in accordance with section 54B of the Narcotic Drugs Regulation 2016. That section likely requires payment within a specified period after the start of the licence year or before the licence year. The holder should check the due date with the regulator, as the regulation does not prescribe it.

Inspection charges are payable when an inspection occurs. The holder should maintain records of all inspections, including the date, the inspector's identity, and the type (type 1 or type 2). If the regulator issues an invoice for an inspection, the holder should verify the classification: type 1 charges ($12,950) apply to compliance monitoring inspections; type 2 charges ($4,920) apply to inspections to verify information. If the holder believes the wrong classification has been applied, they should seek clarification from the regulator before paying, as there is no statutory right to a refund.

The holder should also be aware that multiple inspections in a year are possible and that the absence of a cap means inspection costs are unpredictable. The best way to minimise inspection costs is to maintain full compliance with the Narcotic Drugs Act and licence conditions, thereby reducing the likelihood of type 1 inspections. However, type 2 inspections can be triggered by third-party information, so even compliant holders may face them.

Given the annual amendment history, holders should monitor the Federal Register of Legislation for amendments before the start of each licence year. The charge amounts are not tied to a price index; they are set by regulation and can change unexpectedly. Finally, holders should ensure that any entity that holds multiple licences (e.g., both commercial and non-commercial) treats each licence separately for charge purposes. There is no discount for multiple licences.